Showing posts with label CTLA 2. Show all posts
Showing posts with label CTLA 2. Show all posts

Thursday, April 25, 2013

NEW OPTIMISM IN RECURRENT OVARIAN CANCER

" There is reason to be optimistic about the future of therapy for patients with recurrent ovarian cancer. Inhibition of Wee-1 may target the universal p53 aberrations observed in high-grade serous cancers, and Wee-1 inhibitors are being developed. Objective responses to a variety of immune therapies have been observed, such as an antibody against cytotoxic T-lymphocyte protein 4 (CTLA 4) (see reference 66 from Vaughn et al[9]) or BMS-936559, and antiprogrammed death ligand-1 (PDL-1) monoclonal antibody[15] and immune therapies are a promising area for development. Aberrant DNA methylation is a frequent epigenetic event in ovarian cancer, and the use of chemotherapy plus epigenetic modulators such as demethylating agents or histone deacetylase inhibitors is being studied. The ability to analyze complex genomic data is rapidly increasing, and ovarian cancer is fairly readily biopsiable. More than ever, patients with recurrent disease should consider participation in high quality research trials."

"the addition of PARP inhibitors to chemotherapy in women with recurrent disease has so far failed to improve survival.[14] Front-line trials with PARP inhibitors are being planned, and may yield better results"
                      
 FROM: 
Management of Recurrent EOC: The State of the Art
By Gini F. Fleming, MD1 | April 15, 2013
 ---------------------------------------------------------------------------------------
WE ARE GOING TO FURTHER COMMENTS OF THESE NEW OPTIONS AS WE LEARN MORE! 
MAY BE WE SHOULD BE ADDING INHIBITORS OF AURORA (s) INSTEAD  !